Dr. Sagar Parikh, MD Appointed to NeonMind Specialty Clinics Advisory Board
DISCLAIMER: Please note the date of the release appears in real time and will automatically update as your release crosses the wires. To make changes to your release for please email accesswire.com
or call our News Desk Team at 888-952-4446x1. If there is a problem with your news distribution, please note that ACCESSWIRE must be contacted no more than 90 minutes after your intended
cross time in order to be of assistance. Any correspondence received outside of this timeframe will be dealt with at the discretion of management. Per our corporate policy, this release will not be made
public without your direct approval.
Dr. Sagar Parikh, MD Appointed to NeonMind Specialty Clinics Advisory Board
VANCOUVER, BC / ACCESSWIRE / July 28, 2021 / NeonMind Biosciences Inc.
(CSE:NEON)(OTCQB:NMDBF)(FFE:6UF) ("NeonMind'' or the "Company"), an integrated drug development and
wellness company focused on the potential therapeutic uses of psilocybin for treating obesity and weight management
conditions, announced today the appointment of Dr. Sagar Parikh, MD to its Specialty Clinics Advisory Board. In this
role, Dr. Parikh will leverage his vast expertise in clinical treatment and interventional psychiatry including effectively
treating patients with psychedelics such as ketamine, esketamine, and neurostimulation for mood and anxiety disorders to
guide NeonMind as it develops specialty clinic services for communities in need.
Dr. Parikh has served as the John F. Greden Professor of Depression and Clinical Neuroscience, and Professor of
Psychiatry, at the University of Michigan, Ann Arbor since 2015, where he was also designated Associate Director of the
Michigan Comprehensive Depression Center. He is an adjunct Professor of Psychiatry at the University of Toronto, where
he was on staff full-time from 1994-2015. He serves as the Medical Director at the National Network of Depression
Centers, completed two terms as Deputy Psychiatrist-in-Chief at Toronto's major hospital grouping, the University Health
Network, and was head of the Bipolar Clinic and Director of CME at the Centre for Addiction and Mental Health
(CAMH) in Toronto.
"Dr. Parikh brings unmatched experience to guide the development and integration of the most effective and cutting-edge
protocols and treatment modalities for our expected specialty clinic rollout. We are committed to ensuring that every
patient receives tailored, personalized care and each clinic is designed to meet needs of the local community where it will
be located. Dr. Parikh's expert leadership will ensure that we offer best-in-class medical services and programs to every
patient," said Robert Tessarolo, President & CEO of NeonMind.
On his appointment, Dr. Parikh said, "NeonMind is developing a network of clinics that is truly unique in its
specialization and breadth of treatment offerings. As mental health care continues to evolve at a rapid pace with new
treatments and protocols, NeonMind will be well positioned to have the programs, infrastructure, and education in place
to safely and effectively administer these treatments."
Dr. Sagar Parikh is the author/editor of three books and over 200 peer-reviewed articles and book chapters, and co-author
of CANMAT treatment guidelines for Depression and for Bipolar Disorder, the world's most cited mood disorder
guidelines. He holds research grants from multiple funding agencies, covering studies in clinical treatments in mood
disorders, health services research, genetics, epidemiology, and educational research. He has conducted clinical trials
DISCLAIMER: Please note the date of the release appears in real time and will automatically update as your release crosses the wires. To make changes to your release for please email accesswire.com
or call our News Desk Team at 888-952-4446x1. If there is a problem with your news distribution, please note that ACCESSWIRE must be contacted no more than 90 minutes after your intended
cross time in order to be of assistance. Any correspondence received outside of this timeframe will be dealt with at the discretion of management. Per our corporate policy, this release will not be made
public without your direct approval.
looking at the combination of medication and psychotherapy for bipolar disorder and for depression, as well as
pharmacotherapy trials in mood disorders.
About NeonMind Biosciences Inc.
NeonMind is engaged in preclinical research to develop potential clinical treatments and wellness products to address
obesity and weight management conditions and to promote health and wellness. The Company operates three divisions: (i)
a pharmaceutical division engaged in drug development of psychedelic compounds with two lead psilocybin-based drug
candidates targeting obesity; (ii) a medical services division focused on launching specialty mental health clinics that
integrate psychedelic therapeutics into traditional psychotherapy settings; and (iii) a consumer products division that
currently sells mushroom-infused products to promote health and wellness.
In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs targeting obesity.
NeonMind's first drug candidate employs psilocybin as an agonist at the serotonin 5- HT2A receptor, which is involved in
the hallucinogenic effect of psychedelics. The Company's second drug candidate employs low-dose psilocybin as an
agonist at the 5-HT2C receptor, which controls appetite.
NeonMind established a medical services division with the goal of launching NeonMind-branded specialty mental health
clinics in Canada that incorporate evidence-backed innovative treatments to address a variety of mental health needs.
NeonMind's consumer division currently sells NeonMind-branded coffee products in the United States and Canada
through NeonMind's direct to consumer e-commerce platform.
For more information on NeonMind, go to www.NeonMindBiosciences.com.
Rob Tessarolo, President & Chief Executive Officer, NeonMind Biosciences Inc.
Tel: 416-750-3101
Investor Relations:
KCSA Strategic Communications
Scott Eckstein/Tim Regan
Tel: 212-896-1210
Media Inquiries:
KCSA Strategic Communications
Annie Graf
Tel: 786-390-2644
The Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this news release.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements contained in this press release constitute forward-looking information. These statements relate to
future events or NeonMind's future performance. The use of any of the words "could", "expect", "believe", "will",
"projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are
intended to identify forward-looking information and are based on NeonMind's current belief or assumptions as to the
outcome and timing of such future events. Actual future results may differ materially. In particular, NeonMind's drug
development plans, its ability to retain key personnel, and its expectation as to the development of its intellectual property
and other steps in its preclinical and clinical drug development constitute forward-looking information. Actual results and
developments may differ materially from those contemplated by forward-looking information. Readers are cautioned not
DISCLAIMER: Please note the date of the release appears in real time and will automatically update as your release crosses the wires. To make changes to your release for please email accesswire.com
or call our News Desk Team at 888-952-4446x1. If there is a problem with your news distribution, please note that ACCESSWIRE must be contacted no more than 90 minutes after your intended
cross time in order to be of assistance. Any correspondence received outside of this timeframe will be dealt with at the discretion of management. Per our corporate policy, this release will not be made
public without your direct approval.
to place undue reliance on forward-looking information. The statements made in this press release are made as of the
date hereof. NeonMind disclaims any intention or obligation to publicly update or revise any forward-looking
information, whether as a result of new information, future events or otherwise, except as may be expressly required by
applicable securities laws.
SOURCE: NeonMind Biosciences Inc.